Clinical MRI for iron detection in Parkinson's disease

Clinical Imaging

Volumn 37, Issue 4, 2013, Pages 631-636

  Rossi, Maija ^a   Ruottinen, Hanna ^a   Soimakallio, Seppo ^a,b   Elovaara, Irina ^a,b   Dastidar, Prasun ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Iron; Magnetic resonance imaging; Parkinson's disease

Indexed keywords

CLINICAL INVESTIGATION; GLOBUS PALLIDUS; HEALTHY VOLUNTEERS; IRON DETECTION; MOTOR IMPAIRMENTS; NEURODEGENERATION; PARKINSON'S DISEASE; SUBSTANTIA NIGRA;

IRON; MAGNETIC RESONANCE IMAGING;

NEURODEGENERATIVE DISEASES;

IRON;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOBUS PALLIDUS; HUMAN; HYPOKINESIA; IMAGE ANALYSIS; IMAGE DISPLAY; MALE; MOTOR DYSFUNCTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SUBSTANTIA NIGRA; SUSCEPTIBILITY WEIGHTED IMAGING;

ADULT; AGED; AGED, 80 AND OVER; BRAIN MAPPING; CAUDATE NUCLEUS; CORPUS CALLOSUM; DISEASE PROGRESSION; FEMALE; GLOBUS PALLIDUS; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84879250235     PISSN: 08997071     EISSN: 18734499     Source Type: Journal    
DOI: 10.1016/j.clinimag.2013.02.001     Document Type: Article

References (48)

1. Lees AJ, Hardy J, Revesz T Parkinson's disease. Lancet 2009, 373:2055-2066. [Review].
2. Graham JM, Paley MN, Grünewald RA, Hoggard N, Griffiths PD Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000, 12:2423-2431.
3. 1 and DTI study. Neuroimage 2009, 47:435-441.
4. Biundo R, Formento-Dojot P, Facchini S, Vallelunga A, Ghezzo L, Foscolo L, Meneghello F, Antonini A Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci 2011, 310:64-69.
5. Hallgren B, Sourander P The effect of age on the non-haemin iron on in the human brain. J Neurochem 1958, 3:41-51.
6. Aquino D, Bizzi A, Grisoli M, Garavaglia B, Bruzzone MG, Nardocci N, Savoiardo M, Chiapparini L Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology 2009, 252:165-172.
7. Drayer B, Burger P, Darwin R, Riederer S, Herfkens R, Johnson GA MRI of brain iron. AJR 1986, 147:103-110.
8. Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg RJ, Khan A, Ayaz M, Kirsch W, Obenaus A Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005, 23:1-25.
9. Berg D Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms. Neurochem Res 2007, 32:1646-1654.
10. Stankiewicz J, Panter SS, Neema M, Arora A, Batt CE, Bakshi R Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007, 4:371-386.
11. Danielson SR, Andersen JK Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med 2008, 44:1787-1794.
12. Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 2006, 253:26-32.
13. Brar S, Henderson D, Schenck J, Zimmerman EA Iron accumulation in the substantia nigra of patients with Alzheimer disease and Parkinsonism. Arch Neurol 2009, 66:371-374.
14. 2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999, 211:489-495.
15. Zhang J, Zhang Y, Wang J, Cai P, Luo C, Qian Z, Dai Y, Feng H Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res 2010, 1330:124-130.
16. Martin WR, Wieler M, Gee M Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008, 70:1411-1417.
17. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114:1953-1975.
18. Ryvlin P, Broussolle E, Piollet H, Viallet F, Khalfallah Y, Chazot G Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol 1995, 52:583-588.
19. Wallis LI, Paley MN, Graham JM, Grünewald RA, Wignall EL, Joy HM, Griffiths PD MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 2008, 28:1061-1067.
20. 2 relaxation time in patients with Parkinson's disease. Neurology 1993, 43:697-700.
21. Griffiths PD, Dobson BR, Jones GR, Clarke DT Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999, 122:667-673.
22. Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schäfer A, Peters AM, Bowtell RW, Auer DP, Gowland PA, Bajaj NP High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 2012, 35:48-55.
23. 2 and assays of iron and ferritin in Parkinson and Huntington disease. Am J Neuroradiol 1993, 14:275-281.
24. 2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy?. Arch Neurol 1999, 56:225-228.
25. Fahn S, Elton RL UPDRS program members. Unified Parkinsons Disease Rating Scale 1987, 153-163. Macmillan Healthcare Information, Florham Park, NJ. S. Fahn, C.D. Marsden, M. Goldstein, D.B. Calne (Eds.).
26. 2* mapping in patients after matrix-associated autologous chondrocyte transplantation: initial results on clinical use with 3.0-Tesla MRI. Eur Radiol 2010, 20:1515-1523.
27. 2* mapping of articular cartilage. Invest Radiol 2008, 43:619-626.
28. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. Am J Neuroradiol 2009, 30:19-30.
29. Mittal S, Wu Z, Neelavalli J, Haacke EM Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. Am J Neuroradiol 2009, 30:232-252.
30. 2-weighted turbo-spinecho sequence with high sampling efficiency (SPACE) for high spatial resolution imaging: initial clinical experiences. Invest Radiol 2005, 40:754-760.
31. Smith SM Fast robust automated brain extraction. Human Brain Mapp 2002, 17:143-155.
32. Zhang Y, Brady M, Smith S Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001, 20:45-57.
33. Braak H, Müller CM, Rüb U, Ackermann H, Bratzke H, de Vos RA, Del Tredici K Pathology associated with sporadic Parkinson's disease-where does it end?. J Neural Transm Suppl 2006, 70:89-97.
34. Schwarz J, Weis S, Kraft E, Tatsch K, Bandmann O, Mehraein P, Vogl T, Oertel WH Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1996, 60:98-101.
35. Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, Tishler TA, Marder SR, Mintz J MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 1999, 17:213-222.
36. Pfefferbaum A, Adalsteinsson E, Rohlfing T, Sullivan EV MRI estimates of brain iron concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI) methods. Neuroimage 2009, 47:493-500.
37. 2-weighted- and FLAIR-SPACE. Invest Radiol 2010, 45:795-802.
38. Ogg RJ, Langston JW, Haacke EM, Steen RG, Taylor JS The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. Magn Reson Imaging 1999, 17:1141-1148.
39. Haacke EM, Makki M, Ge Y, Maheshwari M, Sehgal V, Hu J, Selvan M, Wu Z, Latif Z, Xuan Y, Khan O, Garbern J, Grossman RI Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009, 29:537-544.
40. Kirsch W, McAuley G, Holshouser B, Petersen F, Ayaz M, Vinters HV, Dickson C, Haacke EM, Britt W, Larseng J, Kim I, Mueller C, Schrag M, Kido D Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. J Alzheimers Dis 2009, 17:599-609.
41. 2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol India 2004, 52:332-337.
42. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45:1138-1143.
43. Bartzokis G, Aravagiri M, Oldendorf WH, Mintz J, Marder SR Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn Reson Med 1993, 29:459-464.
44. Helmich RC, Janssen MJ, Oyen WJ, Bloem BR, Toni I Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol 2011, 69:269-281.
45. 2 relaxometry. Magn Reson Med 2005, 53:1202-1206.
46. 0. Magn Reson Med 2002, 48:867-876.
47. Gossuin Y, Muller RN, Gillis P Relaxation induced by ferritin: a better understanding for an improved MRI iron quantification. NMR Biomed 2004, 17:427-432.
48. Gelman N, Gorell JM, Barker PB, Savage RM, Spickler EM, Windham JP, Knight RA MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 1999, 210:759-767.